ERC Starting Grant · 2017
Nanomaterials in Oncology: Exploiting the Intrinsic Cancer-Specific Toxicity of Nanoparticles.
In our current society, therapeutic strategies against cancer suffer from dose-limiting toxicity, lack of specificity and high morbidity. To overcome this, the use of nanomaterials (NMs) is rising, where several NM formulations are undergoing clinical trials or are used in clinics where the NMs are used as drug delivery vehicles or as mediators in physical anticancer methods (e.g. hyperthermia), where to date, the success rate is limited due to low tumor targeting efficacy, lack of specificity and frequent re-use of classical toxicity mechanisms. To overcome these issues, this research program aims to exploit the intrinsic toxicity of certain types of metal-based, degradation-prone NMs…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.